Clinical challenges and unmet needs in the management of complicated skin and skin structure, and soft tissue infections

Surgical Infections

Volumn 6, Issue SUPPL. 2, 2005, Pages

  Turina, Matthias ^a   Cheadle, William G ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DIGOXIN; GATIFLOXACIN; LEVOFLOXACIN; LINCOSAMIDE DERIVATIVE; LINEZOLID; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; NITROIMIDAZOLE DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABIES VACCINE; STREPTOGRAMIN DERIVATIVE; SULTAMICILLIN; TETANUS TOXOID; TIGECYCLINE; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BITE WOUND; CELLULITIS; CLINICAL TRIAL; DEBRIDEMENT; DECUBITUS; DIABETIC FOOT; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG COST; DRUG HALF LIFE; DRUG POTENTIATION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION SENSITIVITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NECROTIZING FASCIITIS; OUTPATIENT CARE; PRIORITY JOURNAL; RABIES; RECURRENT INFECTION; REVIEW; SEPSIS; SKIN FLORA; SKIN INFECTION; SOFT TISSUE INFECTION; SUPPURATIVE HIDRADENITIS; SURGICAL INFECTION; TETANUS; TREATMENT FAILURE; WOUND INFECTION;

EID: 26444618716     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2005.6.2s-23     Document Type: Review

References (68)

1. From the Centers for Disease Control and Prevention. Soft tissue infections among injection drug users - San Francisco, California, 1996-2000. JAMA 2001;285: 2707-2709.
2. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 2004; 53(Suppl 2):ii37-ii50.
3. Ahrenholz DH. Necrotizing soft-tissue infections. Surg Clin North Am 1988;68:199-214.
4. Galbut DL, Gerber DL, Belgraier AH. Spontaneous necrotizing fasciitis. Occurrence secondary to occult diverticulitis. JAMA 1977;238:2302.
5. Hart GB, Lamb RC, Strauss MB. Gas gangrene. J Trauma 1983;23:991-1000.
6. Giuliano A, Lewis F, Jr., Hadley K, et al. Bacteriology of necrotizing fasciitis. Am J Surg 1977;134:52-57.
7. Fry DE. Infections of the Skin and Soft Tissues. In: Chorpenning NE, ed. Surgical Infections. Boston/New York/Toronto /London: Little, Brown and Company, 1994: 145-226.
8. Simmons RL, Ahrenholz.D.H. Infections of the Skin and Soft Tissues. In: Howard RJ, Simmons RL, eds. Surgical Infectious Diseases. New York: Appleton-Century-Crofts, 1988: 377-441.
9. Lewis RT. Soft tissue infections. World J Surg 1998: 22:146-151.
10. Furste W: Tetanus: a new threat. J Trauma. 2001: 51(2):416-417.
11. Lewis RT. Necrotizing soft-tissue infections. Infect Dis Clin North Am. 1992, 6(3):693-703.
12. Wall DB, Klein SR, Black S, et al. A simple model to help distinguish necrotizing fasciitis from non-necrotizing soft tissue infection. J Am Coll Surg 2000;191: 227-231.
13. Freischlag JA, Ajalat G, Busuttil RW. Treatment of necrotizing soft tissue infections. The need for a new approach. Am J Surg 1985;149:751-755.
14. Carroll JA. Common bacterial pyodermas. Taking aim against the most likely pathogens. Postgrad Med 1996;100:311-322.
15. Fitzpatrick TB, Eisen AZ, Wolff KFIM et al. Dermatology in General Medicine. New York: McGraw-Hill, Inc., 1987.
16. O'Dell ML. Skin and wound infections: an overview. Am Fam Physician 1998;57:2424-2432.
17. Fleisher GR. The management of bite wounds. N Engl J Med 1999;340:138-140.
18. Smith PF, Meadowcroft AM, May DB. Treating mammalian bite wounds. J Clin Pharm Ther 2000;25:85-99.
19. Talan DA, Citron DM, Abrahamian FM, et al. Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med 1999;340:85-92.
20. Kelly IP, Cunney RJ, Smyth EG, et al. The management of human bite injuries of the hand. Injury 1996;27:481-484.
21. Goldstein EJ. Bite wounds and infection. Clin Infect Dis 1992;14:633-638.
22. Presutti RJ. Bite wounds. Early treatment and prophylaxis against infectious complications. Postgrad Med 1997;101:243-52, 254.
23. Lipsky BA. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 2004;20(Suppl 1):S68-S77.
24. van Baal JG. Surgical treatment of the infected diabetic foot. Clin Infect Dis 2004;39(Suppl 2):S123-S128.
25. Lepantalo M, Biancari F, Tukiainen E. Never amputate without consultation of a vascular surgeon. Diabetes Metab Res Rev 2000;16(Suppl 1):S27-S32.
26. Steed DL, Donohoe D, Webster MW, et al. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg 1996;183:61-64.
27. Rauwerda JA. Foot debridement: anatomic knowledge is mandatory. Diabetes Metab Res Rev 2000; 16(Suppl 1):S23-S26.
28. Wiseman MC. Hidradenitis suppurativa: a review. Dermatol Ther 2004;17:50-54.
29. Jemec GB, Heidenheim M, Nielsen NH. Hidradenitis suppurativa - characteristics and consequences. Clin Exp Dermatol 1996;21:419-423.
30. Slade DE, Powell BW, Mortimer PS. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg 2003;56:451-461.
31. Banerjee AK. Surgical treatment of hidradenitis suppurativa. Br J Surg 1992;79:863-866.
32. Mitchell KM, Beck DE. Hidradenitis suppurativa. Surg Clin North Am 2002;82:1187-1197.
33. Dalrymple JC, Monaghan JM. Treatment of hidradenitis suppurativa with the carbon dioxide laser. Br J Surg 1987;74:420.
34. Whittington KT, Briones RB. National prevalence and incidence study: six-year sequential acute care data. Adv Skin Wound Care 2004;17:490-494.
35. Sorensen JL, Jorgensen B, Gottrup F. Surgical treatment of pressure ulcers. Am J Surg 2004;188:42-51.
36. Ozyazgan I, Kontacs O. Basal cell carcinoma arising from surgical scars: a case and review of the literature. Dermatol Surg 1999;25:965-968.
37. Foster RD, Anthony JP, Mathes SJ, et al. Ischial pressure sore coverage: a rationale for flap selection. Br J Plast Surg 1997;50:374-379.
38. Livesley NJ, Chow AW. Infected pressure ulcers in elderly individuals. Clin Infect Dis 2002;35:1390-1396.
39. Garg M, Rubayi S, Montgomerie JZ. Postoperative wound infections following myocutaneous flap surgery in spinal injury patients. Paraplegia 1992;30: 734-739.
40. El Azizi M, Rao S, Kanchanapoom T, et al. In-vitro, activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci. Ann Clin Microbiol Antimicrob 2005;4:2.
41. Diep BA, Sensabaugh GF, Somboona NS, et al. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J Clin Microbiol 2004;42:2080-2084.
42. Ellis MW, Hospenthal DR, Dooley DP, et al. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 2004;39:971-979.
43. Young DM, Harris HW, Charlebois ED, et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg 2004;139:947-951.
44. Fagan SP, Berger DH, Rahwan K, et al. Spider bites presenting with methicillin-resistant Staphylococcus aureus soft tissue infection require early aggressive treatment. Surg Infect (Larchmt) 2003;4:311-315.
45. Anaya DA, McMahon K, Nathens AB, et al. Predictors of mortality and limb loss in necrotizing soft tissue infections. Arch Surg 2005;140:151-157.
46. Franklin GA, Moore KB, Snyder JW, et al. Emergence of resistant microbes in critical care units is transient, despite an unrestricted formulary and multiple antibiotic trials. Surg Infect (Larchmt) 2002;3:135-144.
47. Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 2004;64: 1621-1642.
48. Martin SJ, Zeigler DG. The use of fluoroquinolones in the treatment of skin infections. Expert Opin Pharmacother 2004;5:237-246.
49. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004;38(Suppl 4):S341-S345.
50. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (in press).
51. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999;44:263-273.
52. Stevens DL, Dotter B, Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2004;2:51-59.
53. Weigelt J, Kaafarani HM, Itani KM, et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004;188:760-766.
54. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673-1681.
55. Guay DR. Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy 2004;24:58-68.
56. Betriu C, Culebras E, Rodriguez-Avial I, et al. In-vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance. Antimicrob Agents Chemother 2004;48:323-325.
57. Fritsche TR, Jones RN. Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int J Antimicrob Agents 2004;24:567-571.
58. Fritsche TR, Kirby JT, Jones RN. In-vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004;49:201-209.
59. Jacobus NV, McDermott LA, Ruthazer R, et al. In-vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother 2004;48: 1034-1036.
60. Kitzis MD, Ly A, Goldstein FW. In-vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2004;48:366-367.
61. Sun HK, Christine CT, Umer A, et al. Pharmacokinetic profile of tigecycline in serum and blister fluid after multiple intravenous administrations in healthy adults. Antimicrob Agents Chemother 2005;49:1629-1632.
62. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220-229.
63. Zimmermann JJ, Harper D, Matschke K, et al. Pharmacokinetics and pharmacodynamics of tigecycline and digoxin coadministered to healthy men. Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2004; A-460.
64. Stevens T, Johnson B, Bouchillon S, et al. Tigecycline evaluation surveillance trial (T.E.S.T.) - In-vitro antibacterial activity against selected species of Enterobacteriaceae. Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2004; E-2060
65. Ong CT, Babalola CP, Nightingale CH, et al. Penetration, intracellular accumulation, and efflux of tigecycline in human polymorphonuclear neutrophils (PMNs). Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2004; (oral presentation).
66. Dartois N. Results of a phase 3, double-blind, safety and efficacy study comparing tigecylcline with vancomycin/aztreonam to treat complicated skin and skin structure infections. Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2004; L-986.
67. Ellis-Grosse EJ, Loh E. Tigecycline is safe and effective in the treatment of skin and skin structure infections. Results of two double-blind phase 3 comparison studies with vancomycin/aztreonam. Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2004.
68. Postier RG, Green SL, Klein SR, et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004;26:704-714.